Anzeige
Meldung des Tages: Early Bird Special: Ad-hoc im Schatten einer milliardenschweren Entscheidung

Neurocrine Biosc. News

Aktie
WKN:  900964 ISIN:  US64125C1099 US-Symbol:  NBIX Branche:  Pharmazeutika Land:  USA
112,43 €
+0,05 €
+0,04%
12:43:05 Uhr
Depot/Watchlist
Marktkapitalisierung *
12,30 Mrd. €
Streubesitz
-
KGV
20,38
Nachhaltigkeits-Score
55 %
Index-Zuordnung
-
Weiter aufwärts? Long handeln - Jetzt mit Hebel 6,10: MN4HCE
Werbung

Neurocrine Biosciences News

01.05.26 - PR Newswire
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful ...
29.04.26 - PR Newswire
Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale
Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale PR Newswire
22.04.26 - PR Newswire
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in ...
14.04.26 - PR Newswire
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results PR Newswire
14.04.26 - PR Newswire
Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR
Neurocrine Biosciences Presents First Real-​World Head-​to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules ...
06.04.26 - PR Newswire
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio PR Newswire
26.03.26 - PR Newswire
Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings
Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings PR Newswire
17.03.26 - PR Newswire
Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer
Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer PR Newswire
10.03.26 - PR Newswire
Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum
Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum PR Newswire
06.03.26 - PR Newswire
BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX)
BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX) PR Newswire
24.02.26 - PR Newswire
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March PR Newswire
11.02.26 - PR Newswire
Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026
Neurocrine Biosciences Reports Fourth-​Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026 PR Newswire
26.01.26 - PR Newswire
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia PR Newswire
21.01.26 - PR Newswire
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results PR Newswire
15.01.26 - PR Newswire
Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR
Neurocrine Biosciences Presents Head-​to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR PR Newswire
05.01.26 - PR Newswire
Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire
22.12.25 - PR Newswire
Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy
Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy PR Newswire
16.12.25 - PR Newswire
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology PR Newswire
09.12.25 - PR Newswire
Neurocrine Biosciences to Host R&D Day on December 16
Neurocrine Biosciences to Host R&D Day on December 16 PR Newswire
20.11.25 - PR Newswire
Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules
Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-​Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) ...

Newssuche

Videos

newspaper
26.04.26
Big Fish Strategy Einführung
Strategie-​Paket inklusive Live-​Webinar am 3.5., Videoaufzeichnung, Unterlagen und Nachbetreuung JETZT ... Mehr »
Anzeige

Aktie im Fokus

Mit Graphen gegen jede Abwehr
Plaid Technologies
0,396 €
+7,03%
Plaid Technologies Chart
Die Zukunft der Drohnen ist da
Mehr zur Aktie »